AI is dramatically changing the landscape of drug discovery in research today, but what is needed for the best outcomes? How do we overcome the challenges?

Artificial intelligence is not the future anymore; it is happening now – and it is happening on a grand scale.

Academic researchers and pharmaceutical companies have started utilising AI to aid in drug discovery. Drug discovery is a lengthy and costly process, with average research and development for new drugs taking 10-20 years and costing billions of dollars. New approaches are needed, and looking to AI might unlock potential that we have not yet imagined. But are there costs?

Listen as an expert in AI and machine learning and an experimental biologist discuss the evolution, applications of AI and its possible uses in medical research.

Guests:

Per Greisen, Director of Computational Drug Discovery at Novo Nordisk.

Hande Topel, Postdoctoral researcher in a functional genomics and metabolism unit at the University of Southern Denmark

Host:
Gretchen Repasky, Communications Director, Nordic EMBL Partnership for Molecular Medicine and the University of Helsinki.

Publisher:
Danish Diabetes and Endocrine Academy

Producer:
Kontekst & Lyd

You can find additional information about the podcast at www.ddeacademy.dk/podcasts